ResApp develops digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.
We will provide telehealth companies with point of care diagnostic solutions that can be easily integrated into their platforms.
We are working on apps to provide instant clinical quality diagnostic tests and management tools directly to consumers and healthcare providers.
A world-leading technology platform
Over the last five years the research team, led by Associate Professor Udantha Abeyratne at The University of Queensland, has pioneered algorithms that accurately characterise the state of patients’ respiratory tracts. The team has created a powerful platform for respiratory disease diagnosis and management which only requires the sound of the patient’s cough or breathing and does not require physical contact. With the high quality microphones in today’s smartphones the platform can be delivered without the need for additional hardware.
New mHealth Study to Test the Smartphone’s Diagnostic Capabilities
mHealth Intelligence – 16 November 2016
In what could be a pivotal test of the diagnostic capabilities of a smartphone, three prominent U.S. health systems are ready to conduct clinical trials on an app that analyzes a user’s cough. Baylor College of Medicine and Texas Children’s Hospital, the Cleveland Clinic and Massachusetts General Hospital have received institutional review board (IRB) approval for the SMARTCOUGH-C study, which will look to determine whether ResApp Health Limited’s ResAppDx app can diagnose pneumonia and other common respiratory diseases in children. Read the article
ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000
© 2017 ResApp Health Limited. All Rights Reserved.